论文部分内容阅读
Owren等研究出不受内因性凝血抑制因子即维生素K缺乏时血肉出现的蛋白质(Protein induced vitaminK absence;PIVKA)影响,而能准确测定出肝胆疾病时减低之第Ⅱ、Ⅶ和Ⅹ三种凝血因子的技术。此种检测技术能反映出正常和低于正常值的凝血功能变动状况,可测出10～200%凝血活动度,且系标准化的方法,故命名为“Normotest”,日本称之为“Hepaplastin test(HPT)”,我们暂且译作肝促凝血酶原激酶试验。HPT试剂可灵敏而确切地反映出肝脏的凝血蛋白合成功能,从而得以真实地测出
Owren and other studies have been developed from the intrinsic factor of coagulation inhibitors that vitamin K deficiency flesh-and-blood protein (ProteinIVvok); PIVKA influence, and can accurately determine the reduction of hepatobiliary disease Ⅱ, Ⅶ and Ⅹ three coagulation factors Technology. This detection technique can reflect the normal and lower than normal coagulation changes, measurable 10 ~ 200% coagulation activity, and the Department of standardized methods, so named “Normotest”, Japan called “Hepaplastin test (HPT) ”, we for the time being translated as thromboplastin test. HPT reagent can sensitively and accurately reflect the hepatic coagulation protein synthesis function, which can be truly measured